Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.ĭisclaimer : ICICI Securities attempts to ensure the highest level of integrity, correctness and authenticity of the content and data updated on the site. 20200831-45 dated Augand other guidelines issued from time to time in this regard. 20200731-7 dated Jand NSE Circular Reference No. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide NSE circular reference NSE/INSP/45191 dated JBSE Notice no. Pay minimum 20% upfront margin of the transaction value to trade in cash market segment. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. is just acting as a distributor/ referral Agent of such products / services and all disputes with respect to the distribution activity would not have access to Exchange investor redressal or Arbitration mechanism. are not exchange traded products / services and ICICI Securities Ltd. The non-broking products / services like Mutual Funds, Insurance, FD/ Bonds, loans, PMS, Tax, Elocker, NPS, IPO, Research, Financial Learning, ESOP funding etc. United States: US business revenues saw a slight decrease of 6% to Rs 274 crore, with constant currency revenues down by 7%, affected by a lack of new product launches.Germany: Achieved revenues of Rs 270 crore, increasing by 12%, with constant currency revenues rising by 6% due to tender wins.Brazil: Reported revenues of Rs 312 crore, growing by 26%, with constant currency revenues up by 17%.India: Revenues reached Rs 1,415 crore, up by 12%, outperforming the market in focus therapies.Net Profit Margin: The net profit margin stood at 16%, representing the profitability from the revenue earned.Interest Service Coverage Ratio: Standing at 9.08, showing a strong ability to meet interest expenses.Debt Service Coverage Ratio: At 2.21, suggesting the company's ability to service its debt is well-managed.Debt Equity Ratio: A ratio of 0.53, indicating a moderate level of debt in comparison to equity. Research & Development (R&D) Spend: Rs 127 crore, reaffirming the company's commitment to innovation.Net Profit After Tax (PAT): Rs 443 crore, marking a significant 52% surge.Exceptional Items: Gained net proceeds of Rs 88 crore from the sale of a US facility.Operational EBITDA: Rs 869 crore, experiencing a 20% growth.Gross Margin: 75%, maintaining a stable position in the market.Revenue: Rs 2,732 crore, indicating a 10% increase.Torrent Pharmaceuticals announced Q3FY24 results: Financial Performance for Q3FY24: Q3FY24 Quarterly Result Announced for Torrent Pharmaceuticals Ltd.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |